Your browser doesn't support javascript.
loading
Interleukin 2 increases protection against experimental rabies.
Perrin, P; Joffret, M L; Leclerc, C; Oth, D; Sureau, P; Thibodeau, L.
Afiliação
  • Perrin P; Unité de la Rage, Institut Pasteur, Paris, France.
Immunobiology ; 177(2): 199-209, 1988 May.
Article em En | MEDLINE | ID: mdl-3261273
ABSTRACT
Vaccination with either whole inactivated rabies virus or immunosome (rabies glycoprotein anchored on liposomes) induces a high level of interleukin 2 (IL 2) production after in vitro specific stimulation of splenocytes from primed mice (9). On the contrary, infection with a live rabies virus does not specifically induce the production of IL 2 splenocytes from ill mice previously infected with wild rabies virus cannot be specifically stimulated by rabies antigens, whereas they can be non-specifically stimulated by a mitogen (Concanavalin A (Con A]. When injected in mice, exogenous IL 2 (purified rat IL 2 or human recombinant IL 2) exhibits an adjuvant effect on rabies virus vaccine or subunit vaccine tested in a pre-exposure potency test (NIH test). When injected in hamsters, according to a post-exposure potency test (infection with a wild rabies virus followed by vaccination), IL 2 has no adjuvant effect on the rabies vaccine. Nevertheless, when injected alone, IL 2 protects thirty to fifty percent of the infected animals treated (1 hour, 3 and 7 days post-infection) with 10 international units of human recombinant IL 2.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Raiva / Vacina Antirrábica / Linfócitos / Interleucina-2 Limite: Animals Idioma: En Ano de publicação: 1988 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Raiva / Vacina Antirrábica / Linfócitos / Interleucina-2 Limite: Animals Idioma: En Ano de publicação: 1988 Tipo de documento: Article